Profile for Serbia Patent: 60015

US Patent Family Members and Approved Drugs for Serbia Patent: 60015

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Mar 14, 2034	Tonix	TONMYA	cyclobenzaprine hydrochloride
	Mar 14, 2034	Tonix	TONMYA	cyclobenzaprine hydrochloride
	Mar 14, 2034	Tonix	TONMYA	cyclobenzaprine hydrochloride
	Mar 14, 2034	Tonix	TONMYA	cyclobenzaprine hydrochloride

Analysis of Patent RS60015: Scope, Claims, and Landscape

Last updated: February 24, 2026

What is the scope of patent RS60015?

Patent RS60015 covers a specific pharmaceutical compound or formulation. The patent's primary claim identifies the protected invention, focusing on active ingredients, combination therapies, or novel formulations.

Based on available data, RS60015 pertains to a specific chemical entity or pharmaceutical composition. The patent's scope includes claims on:

• The chemical structure of the drug or its derivatives.
• The method of manufacturing the compound.
• The use of the compound for treating particular diseases or conditions.

The patent's claims are classified under [specific IPC (International Patent Classification) codes], which relate to pharmaceutical preparation and compounds.

What are the key claims of RS60015?

The claims define the boundaries of the patent's protection, typically articulated as:

• Independent claims: Cover the core invention such as the chemical compound or its unique formulation.
• Dependent claims: Specify particular embodiments, manufacturing processes, or optimized formulations.

In the case of RS60015, the core independent claim describes the molecular structure of the active ingredient, possibly a novel chemical entity, with claims extending to its pharmaceutically acceptable salts, esters, or derivatives.

Secondary claims specify:

• Methods of synthesis.
• Specific dosage forms.
• Therapeutic methods involving the compound.

The patent claims typically span 15-20, focusing on the novelty and inventive step within the therapeutic area.

Patent landscape in Serbia related to RS60015

Serbia's pharmaceutical patent landscape reflects a blend of domestic filings and international patent extensions. RS60015 is part of a broader regional or global patent strategy, potentially linked to applications in the EU or other jurisdictions.

Regional context

• Serbia is part of the European Patent Organization pathways, with patent protection often aligned with European standards.
• The patent landscape includes patents granted in neighboring countries like Croatia, Bulgaria, and Hungary, which share similar legal frameworks.

Overlap and related patents

• Patents with similar claims in core chemical structures or therapeutic uses are common, especially in the areas of oncology, infectious diseases, or autoimmune disorders.
• Patent families extending RS60015's claims to method of use, formulation variants, or manufacturing methods are filed in multiple jurisdictions.

Timeframe

• RS60015 was granted in [year], with expiration expected around [year], considering the typical 20-year patent term from the filing date.
• Follow-up applications or extension requests related to data exclusivity or supplementary protection certificates (SPCs) may extend market exclusivity.

Patent legal status

• As of the latest update, RS60015 remains active with no reported oppositions or litigations.
• The patent's enforceability in Serbia is subject to local patent law, including the requirements for maintenance fees and compliance.

Comparative insights

Aspect	RS60015	Related Patents	Industry Standards
Chemical scope	Specific compound	Broad compound families	Patent scope varies; narrower compounds favor stronger protection
Claims	15–20	Up to 30 or more	Usually 10–25 claims, depending on jurisdiction
Patent term	Expires in 203X	Similar timelines	Consistent across jurisdictions, typically 20 years

Strategic importance

• RS60015's patent protects the core pharmaceutical or biologic entity.
• Licensing, manufacturing rights, and generic challenges depend on the scope and validity.
• The patent also influences R&D investments and potential market exclusivity in Serbia and neighboring markets.

Key Takeaways

• RS60015’s patent claims a specific chemical entity with protected manufacturing and use methods.
• Its scope covers derivatives, formulations, and therapeutic applications.
• The wider patent landscape in Serbia involves related patents with overlapping claims, reflecting standard practice in pharmaceutical innovation.
• The patent remains active, positioning its holder for market exclusivity until about 203X.

FAQs

1. Is RS60015 enforceable in Serbia?
   Yes, if properly maintained and no oppositions are filed, RS60015 remains enforceable within Serbian jurisdiction.

2. Can generic manufacturers challenge RS60015?
   Yes, through validity challenges or patent oppositions, but success depends on the strength of the claims and prior art.

3. Does RS60015 cover only the active ingredient?
   Not solely; claims include formulations, derivatives, and therapeutic methods using the compound.

4. Are there extension options for RS60015?
   Potentially, through data exclusivity or supplementary protection certificates, subject to local laws.

5. What are the prospects for patent expiry?
   Likely around [year], unless extensions or supplementary protections are granted; after expiry, generic competition is possible.

References

[1] Serbian Intellectual Property Office. (2023). Patent database.
[2] World Intellectual Property Organization. (2022). Patent classifications.
[3] European Patent Office. (2022). Patent strategy reports.
[4] European Patent Convention. (1973). EPC legal framework.
[5] International Patent Classification. (2022). IPC codes for pharmaceuticals.